Human recombinant EGF as a drug

Martínez-Carpio, Pedro A.

doi:10.1016/j.medcle.2023.04.034

array:24 ["pii" => "S2387020623003698" "issn" => "23870206" "doi" => "10.1016/j.medcle.2023.04.034" "estado" => "S300" "fechaPublicacion" => "2023-10-13" "aid" => "6274" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2023" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2023;161:318-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0025775323002324" "issn" => "00257753" "doi" => "10.1016/j.medcli.2023.04.018" "estado" => "S300" "fechaPublicacion" => "2023-10-13" "aid" => "6274" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2023;161:318-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "Carta al Editor" "titulo" => "EGF recombinante humano como fármaco" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "318" "paginaFinal" => "319" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Human recombinant EGF as a drug" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pedro A. Martínez-Carpio" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Pedro A." "apellidos" => "Martínez-Carpio" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020623003698" "doi" => "10.1016/j.medcle.2023.04.034" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020623003698?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775323002324?idApp=UINPBA00004N" "url" => "/00257753/0000016100000007/v1_202310060651/S0025775323002324/v1_202310060651/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2387020623003807" "issn" => "23870206" "doi" => "10.1016/j.medcle.2023.09.004" "estado" => "S300" "fechaPublicacion" => "2023-10-13" "aid" => "6314" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Med Clin. 2023;161:320" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Image in medicine" "titulo" => "Erythrasma and the role of Wood's light: A simple diagnosis pearl" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "320" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Eritrasma y el rol de la luz de Wood: una herramienta diagnóstica valiosa" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 724 "Ancho" => 1050 "Tamanyo" => 84219 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Christian Robles-Silva, Leonel Hidalgo, Cristián Vera-Kellet, Cristián Navarrete-Dechent" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Christian" "apellidos" => "Robles-Silva" ] 1 => array:2 [ "nombre" => "Leonel" "apellidos" => "Hidalgo" ] 2 => array:2 [ "nombre" => "Cristián" "apellidos" => "Vera-Kellet" ] 3 => array:2 [ "nombre" => "Cristián" "apellidos" => "Navarrete-Dechent" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020623003807?idApp=UINPBA00004N" "url" => "/23870206/0000016100000007/v2_202311091450/S2387020623003807/v2_202311091450/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2387020623003777" "issn" => "23870206" "doi" => "10.1016/j.medcle.2023.03.034" "estado" => "S300" "fechaPublicacion" => "2023-10-13" "aid" => "6251" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2023;161:317-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Encephalopathy due to anti-GFAP antibodies in a patient with rheumatoid arthritis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "317" "paginaFinal" => "318" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Encefalopatía por anticuerpos anti-GFAP en paciente con artritis reumatoide" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marvin Bueno, Sofia Acero, Paola Zuluaga" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Marvin" "apellidos" => "Bueno" ] 1 => array:2 [ "nombre" => "Sofia" "apellidos" => "Acero" ] 2 => array:2 [ "nombre" => "Paola" "apellidos" => "Zuluaga" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020623003777?idApp=UINPBA00004N" "url" => "/23870206/0000016100000007/v2_202311091450/S2387020623003777/v2_202311091450/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Human recombinant EGF as a drug" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "318" "paginaFinal" => "319" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Pedro A. Martínez-Carpio" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Pedro A." "apellidos" => "Martínez-Carpio" "email" => array:1 [ 0 => "pmc@investilaser.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Unidad de Investigación Clínica, IMC-Investilaser, Sabadell, Barcelona, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "EGF recombinante humano como fármaco" ] ] "textoCompleto" => "I read with great interest an article published in your journal, submitted by Esquirol and Herrero, on the possible therapeutic uses of human recombinant epidermal growth factor (rh-EGF).<a class="elsevierStyleCrossRef" href="#bib0005">1</a> It is a review of the possible indications for topical application of rh-EGF, especially for dermatological conditions (as creams or emulsions) and ophthalmological conditions (as eye drops). The heading of the introduction indicates, without providing any literature reference, that rh-EGF can be formulated in an active and stable form for clinical use, without side effects and with complete safety over prolonged periods of time.The current reality is that rh-EGF is not licensed as a medical treatment and can only be used for clinical trials. All attempts by the pharmaceutical industry to market a cream or eye drops containing rh-EGF have failed. The problem is the total instability of the molecule, which rapidly loses its tertiary structure conformation, as it is well known that obtaining a recombinant replica of 53 amino acids is not enough, but 6 cysteine residues must be correctly positioned so that 3 disulphide bridges can be formed. Without this structure it is impossible for the ligand (EGF) to bind to its receptor (EGFR).<a class="elsevierStyleCrossRefs" href="#bib0010">2,3</a>The authors indicate, through a literature citation of my own authorship, that EGF eye drops are effective and safe for ophthalmological treatments.<a class="elsevierStyleCrossRef" href="#bib0020">4</a> They referred to a meta-analysis of clinical trials that I published in 2012, which showed excellent short-term results for rh-EGF eye drops, without evaluating any mid- or long-term safety data. More than 10 years later, none of these eye drops have been successful. The rh-EGF eye drops are not available in pharmacies. It is only marketed in China, and the molecule is as inactive as the so-called sh-oligopeptide-1 that is used in cosmetics.Nor will we find any product for topical application to the skin that contains pharmaceutical-grade rh-EGF. On the other hand, many cosmetic brands boast of including EGF in their products. These are recombinant molecules synthesised in the manner described by Esquirol and Herrero, but which have not demonstrated pre-clinical efficacy and are being used, inconsistently, for clinical trials in patients. Cosmetics are being used to treat diseases, something highly disturbing and outside the medical norm. European and American legislation prohibits the identification of EGF in the composition of cosmetics. It goes by the name of sh-oligopeptide-1, which can be considered the cosmetic variant of EGF. What the authors may not be aware of is that many of the clinical trials cited in the references have not been conducted with a drug, but with a cosmetic that does not even indicate a dosage in its composition.A review of the literature published up to March 2023 reveals almost twenty inappropriate "clinical trials" conducted with the cosmetic sh-oligopeptide-1. They refer to the oligopeptide as sh-EGF (synthetic human EGF), some even indicate that it is rh-EGF, as used by the pharmaceutical industry in trials.The day a product with active and stable EGF becomes a reality, it should be studied as a drug, not as a cosmetic, and the pharmaceutical industry, not the cosmetic industry, should be in charge of developing the product. rh-EGF is not a cosmetic, it is a potent drug with potential risks, especially cancer.<a class="elsevierStyleCrossRef" href="#bib0025">5</a> Health authorities should keep a close eye on these cosmetics, as with current developments they will end up synthesising risky molecules if they are not sufficiently monitored. Reviewers of scientific journals should not accept any studies using cosmetics to treat diseases. Ethics committees should not accept clinical trials with cosmetics because they do not meet any efficacy guarantees to be used in trials and are outside the medical standard. If any of these recombinant growth factor mimicking peptides show any kind of biological activity, they should be considered a drug of potential risk.<a class="elsevierStyleCrossRef" href="#bib0025">5</a>Finally, the authors indicate that active and stable rh-EGF can be obtained through pharmaceutical compounding, but they do not provide any literature reference. I have been trying to find this citation for 20 years. It did not exist in 2015 when this article was published, nor does it exist today.FundingI have not received any funding." "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Factor de crecimiento epidérmico, innovación y seguridad [Epidermal growth factor, innovation and safety]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Esquirol Caussa" 1 => "E. Herrero Vila" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.medcli.2014.09.012" "Revista" => array:6 [ "tituloSerie" => "Med Clin (Barc)" "fecha" => "2015" "volumen" => "145" "paginaInicial" => "305" "paginaFinal" => "312" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25433777" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidermal Growth Factor forty years after its discovery: from biochemistry to clinical applications" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "P.A. Martínez-Carpio" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Endocrinol Nutr" "fecha" => "2003" "volumen" => "50" "paginaInicial" => "334" "paginaFinal" => "344" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Secretion and dual regulation between epidermal growth factor and transforming growth factor-ß1 in MDA-MB-231 cell line in 42-hour-long cultures" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P.A. Martínez-Carpio" 1 => "C. Mur" 2 => "P. Rosel" 3 => "M.A. Navarro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0304-3835(99)00261-x" "Revista" => array:6 [ "tituloSerie" => "Cancer Lett" "fecha" => "1999" "volumen" => "147" "paginaInicial" => "25" "paginaFinal" => "29" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10660085" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Posology, efficacy, and safety of epidermal growth factor eye drops in 305 patients: logistic regression and group-wise odds of published data" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.M. Lou-Bonafonte" 1 => "E. Bonafonte-Marquez" 2 => "S. Bonafonte-Royo" 3 => "P.A. Martínez-Carpio" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/jop.2011.0236" "Revista" => array:6 [ "tituloSerie" => "J Ocul Pharmacol Ther" "fecha" => "2012" "volumen" => "28" "paginaInicial" => "467" "paginaFinal" => "472" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22537292" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Factores de crecimiento, lesión celular, proteincinasas dependientes de ciclinas y sus inhibidores: su relevancia en la patología molecular del cáncer humano [Growth factors, cell damage, cyclin-dependent kinases and their inhibitors: relevance in molecular pathology of human cancer]" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "P.A. Martínez-Carpio" 1 => "M.A. Navarro Moreno" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0025-7753(03)73673-2" "Revista" => array:6 [ "tituloSerie" => "Med Clin (Barc)" "fecha" => "2003" "volumen" => "120" "paginaInicial" => "265" "paginaFinal" => "271" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12623004" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23870206/0000016100000007/v2_202311091450/S2387020623003698/v2_202311091450/en/main.assets" "Apartado" => array:4 [ "identificador" => "43309" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23870206/0000016100000007/v2_202311091450/S2387020623003698/v2_202311091450/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020623003698?idApp=UINPBA00004N"]

ISSN: 2387-0206

Launched in 1943, Medicina Clínica is a fortnightly journal aimed at the promotion of clinical research and practice among internal medicine and other specialists. The key characteristics of Medicina Clínica are the scientific and methodological rigor of its manuscripts, the topicality of its contents, and, especially, its practical focus with highly useful information for clinical practice. Medicina Clínica is predominantly interested in publishing original research manuscripts, which are rigorously selected according to their quality, originality, and interest, and also in continued medical education-oriented manuscripts, which are commissioned by the journal to relevant authors (Editorials, Reviews, and Diagnosis and Treatment). These manuscripts contain updated topics with a major clinical or conceptual relevance in modern medicine. The journal adheres to the standards of academic research publications in all aspects including peer-review and ethical principles. Medicina Clínica is included in the General and Internal Medicine category of Thomson Reuters.

See more Open Access Option

Indexed in:

Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, SciVerse ScienceDirect

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.6

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.371

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.511

View more metrics

Journal Information

Previous article | Next article

Vol. 161. Issue 7.

Pages 318-319 (October 2023)

Lee este artículo en Español

Export reference

Download PDF

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)

Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”

Subscribe to

Medicina Clínica (English Edition)

More information

Purchase

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now

Contact

Phone for subscriptions and reporting of errors

From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.

Calls from Spain

932 415 960

Calls from outside Spain

+34 932 415 960

E-mail

atencionalcliente@elsevier.com

Publish in

Medicina Clínica

Tools

Free access articles

Early cortical atrophy in REM sleep behavior...

Med Clin. 2024;163:70-3

Disability degree assessment: A comprehensive approach...

Med Clin. 2024;163:e3-e7

Inappropriate hospitalization: Measurement...

Med Clin. 2024;163:91-7

Medicina Clínica (English Edition) follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe:

Article

Subscribe to our newsletter